Skip to ContentSkip to Navigation
Practical matters How to find us A.M.H. Soliman, Dr


Characterization and therapeutic targeting of Parkinson’s-related LRRK2

LRRK2 protects immune cells against erastin-induced ferroptosis

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

Allosteric Inhibition of Parkinson's-Linked LRRK2 by Constrained Peptides

Nanobodies as allosteric modulators of Parkinson’s disease-associated LRRK2

Allosteric inhibition of LRRK2, where are we now

Read more